{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Facon T"],"funding":["NCI NIH HHS"],"pagination":["301-310"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5774211"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["131(3)"],"pubmed_abstract":["This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; <i>P</i> < .00001) and "],"journal":["Blood"],"pubmed_title":["Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma."],"pmcid":["PMC5774211"],"funding_grant_id":["P50 CA186781"],"pubmed_authors":["Catalano JV","Mohty M","Houck V","Cavo M","Moreau P","Anderson KC","Binder D","Qiu L","Leleu X","Dispenzieri A","Ervin-Haynes A","Delforge M","Oriol A","Banos A","Dimopoulos MA","Lee JJ","White D","Facon T","De La Rubia J","Roussel M","Weisel K","Cavenagh JD","Chen G","Bahlis NJ","Geraldes C","Boyle E","Chen C","Manier S","Perrot A","Benboubker L","Hulin C","Attal M","Tiab M","Pinto A","Ludwig H","Lu J","Belch A","Avet-Loiseau H","Arnulf B"],"additional_accession":[]},"is_claimable":false,"name":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.","description":"This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; <i>P</i> < .00001) and ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jan","modification":"2026-05-02T19:25:32.358Z","creation":"2019-03-26T23:52:41Z"},"accession":"S-EPMC5774211","cross_references":{"pubmed":["29150421"],"doi":["10.1182/blood-2017-07-795047"]}}